Comparing SG&A Expenses: ADMA Biologics, Inc. vs Geron Corporation Trends and Insights

Biotech Expense Trends: ADMA vs. Geron

__timestampADMA Biologics, Inc.Geron Corporation
Wednesday, January 1, 2014482386916758000
Thursday, January 1, 2015674596817793000
Friday, January 1, 2016849474218761000
Sunday, January 1, 20171809283519287000
Monday, January 1, 20182250292218707000
Tuesday, January 1, 20192591075720893000
Wednesday, January 1, 20203505081725678000
Friday, January 1, 20214289688929665000
Saturday, January 1, 20225245802443628000
Sunday, January 1, 20235902000069135000
Loading chart...

Unlocking the unknown

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of ADMA Biologics, Inc. and Geron Corporation from 2014 to 2023. Over this period, ADMA Biologics saw a staggering 1,125% increase in SG&A expenses, starting from a modest $4.8 million in 2014 to nearly $59 million in 2023. Meanwhile, Geron Corporation's expenses grew by approximately 312%, from $16.8 million to $69 million.

Key Insights

  • ADMA Biologics: The company's expenses surged, particularly after 2017, reflecting its aggressive growth strategy.
  • Geron Corporation: Despite a slower growth rate, Geron maintained a steady increase, with a notable spike in 2023.

These trends highlight the differing strategic approaches of these companies in navigating the biotech landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025